ReviewPharmaceutics2021
Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarriers.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Green Management Strategies forBiology · 2026Review
- Anti-Inflammatory Effects of Artocarpin-Loaded Chitosan Microparticles on Inflammatory Chondrocytes.Molecules (Basel, Switzerland) · 2026Article
- Liposomes-enabled gemcitabine therapy for breast cancer: in vitro and in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mitochondria-targeted nanozyme system for psoriasis treatment.Journal of nanobiotechnology · 2026Article
- Engineering biopolymer-based nanocarriers for cancer drug delivery: a system-level comparison of chitosan, hemicellulose, and lignin platforms with focus on tumor targeting, biodegradation, and immune modulation.Frontiers in bioengineering and biotechnology · 2026Review
- Overcoming the blood-brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms.Frontiers in neuroscience · 2026Review
- The Nasal Route Redefined: The Impact of Chitosan Nanoparticles on Drug Delivery.Mini reviews in medicinal chemistry · 2026Review
- Chitosan based smart injectable hydrogels for biomedical applications: A comprehensive review.Bioactive materials · 2026Review
- Renoprotective actions of puerarin and the prospects of kidney-targeted nanodelivery.Frontiers in pharmacology · 2026Review
- Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.Scientific reports · 2025Article
- 3D-Printed Microneedles with Controlled Structures for Drug Delivery Study in an Ex Vivo Model.Micromachines · 2025Article
- Chitosan-Based Nanogels in Modern Drug Delivery: Focus on Protein and Gene Applications.Gels (Basel, Switzerland) · 2025Review
- Anticancer efficacy of sericin (silkworm protein) and sericin chitosan conjugated silver nanoparticles against colorectal cancer.Medical oncology (Northwood, London, England) · 2025Article
- Article
- The antimicrobial efficacy of rutin encapsulated chitosan versus multidrug-resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Thyme oil-loaded chitosan microparticles: an antibacterial approach against pathogenic bacteria.3 Biotech · 2025Article
- Natural-Synthetic Hybrid Nanostructures Formed Through the Interaction of Chitosan with Carboxylate-Ended PNIPAM: Structure and Curcumin Encapsulation.Nanomaterials (Basel, Switzerland) · 2025Article
- Application of Chitosan-based Nanogel in Cancer Nanomedicine.Current pharmaceutical design · 2025Review
- Exploring the potential of polymers: advancements in oral nanocarrier technology.Beilstein journal of nanotechnology · 2025Review
- Therapeutic potential of natural polymer-based transdermal drug delivery system for musculoskeletal disorders.Biomaterials translational · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In recent decades, drug delivery systems (DDSs) based on nanotechnology have been attracting substantial interest in the pharmaceutical field, especially those developed based on natural polymers such as chitosan, cellulose, starch, collagen, gelatin, alginate and elastin. Nanomaterials based on chitosan (CS) or chitosan derivatives are broadly investigated as promising nanocarriers due to their biodegradability, good biocompatibility, non-toxicity, low immunogenicity, great versatility and beneficial biological effects. CS, either alone or as composites, are suitable substrates in the fabrication of different types of products like hydrogels, membranes, beads, porous foams, nanoparticles, in-situ gel, microparticles, sponges and nanofibers/scaffolds. Currently, the CS based nanocarriers are intensely studied as controlled and targeted drug release systems for different drugs (anti-inflammatory, antibiotic, anticancer etc.) as well as for proteins/peptides, growth factors, vaccines, small DNA (DNAs) and short interfering RNA (siRNA). This review targets the latest biomedical approaches for CS based nanocarriers such as nanoparticles (NPs) nanofibers (NFs), nanogels (NGs) and chitosan coated liposomes (LPs) and their potential applications for medical and pharmaceutical fields. The advantages and challenges of reviewed CS based nanocarriers for different routes of administration (oral, transmucosal, pulmonary and transdermal) with reference to classical formulations are also emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.